Business
enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants
BOSTON & MONTREAL, November 13, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced the pricing of its previously announced underwritten public offering of 12,558,823 common shares at a public offering price of $8.50 per share and pre-funded warrants to purchase 2,735,295 shares of its common shares at an offering price of $8.4999 per pre-funded warrant, in each case, before underwriting discounts and commis
About this update from Engene Holdings Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/937e9bf2c41ad10bdd001708879af74a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dlrzr3Q8AmYuNipY.0hEwg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/937e9bf2c41ad10bdd001708879af74a","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/EhfMtMvsligiuAp982zjQA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/937e9bf2c41ad10bdd001708879af74a","width":1024,"height":512}},"lazy":false},{"type":"text","content":"BOSTON & MONTREAL, November 13, 2025--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced the pricing of its previously announced underwritten public offering of 12,558,823 common shares at a public offering price of $8.50 per share and pre-funded warrants to purchase 2,735,295 shares of its common shares at an offering price of $8.4999 per pre-funded warrant, in each case, before underwriting discounts and commissions. The aggregate gross proceeds to enGene from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by enGene, are expected to be approximately $130 million. All securities to be sold in the offering will be offered by enGene. In addition, enGene has granted to the underwriters a 30-day option to purchase up to 2,294,117 additional common shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about November 14, 2025, subject to the satisfaction of customary closing conditions.","length":1144,"tagName":"p"},{"type":"text","content":"Jefferies, Leerink Partners and Wells Fargo Securities are acting as joint book running managers for the offering. Raymond James and Van Lanschot Kempen are acting as co-lead managers for the offering. H.C. Wainwright & Co. is acting as co-manager for the offering.","length":269,"tagName":"p"},{"type":"text","content":"The securities described above are being offered by enGene pursuant to its effective shelf registrat...